^(18)F-FDG PET/CT监测免疫相关不良反应的临床应用  

^(18)F-FDG PET/CT in detecting immune-related adverse events

作　　者：王静楠 王雪竹 杨旭 赵海涛 张力 王颖轶 李方 霍力 Wang Jingnan;Wang Xuezhu;Yang Xu;Zhao Haitao;Zhang Li;Wang Yingyi;Li Fang;Huo Li(Department of Nuclear Medicine,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine,Beijing 100730;Department of Liver Surgery,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730;Department of Respiratory,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730;Department of Oncology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730)

机构地区：[1]中国医学科学院、北京协和医学院北京协和医院核医学科、核医学分子靶向诊疗北京市重点实验室,北京100730 [2]中国医学科学院、北京协和医学院北京协和医院肝脏外科,北京100730 [3]中国医学科学院、北京协和医学院北京协和医院呼吸内科,北京100730 [4]中国医学科学院、北京协和医学院北京协和医院肿瘤内科,北京100730

出　　处：《中华核医学与分子影像杂志》2022年第2期118-121,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：中国医学科学院医学与健康科技创新工程 (2018-I2M-3-001)。

摘　　要：免疫检查点抑制剂(ICIs)在国内外临床试验的多种恶性肿瘤治疗中表现出了显著的疗效,在我国已被批准进入临床应用。ICIs治疗引起的免疫相关不良反应(irAEs)可发生于任何器官,早期发现和临床干预能够改善患者预后。^(18)F-FDG PET/CT有助于早期发现irAEs,为临床诊疗提供正确的指导。该文旨在对^(18)F-FDG PET/CT在监测irAEs的临床应用进行综述,总结其典型影像学表现和研究进展。Immune checkpoint inhibitors(ICIs)have shown significant efficacy in clinical trials and applications of various malignant tumors,and have been approved for clinical application in China.ICIs can cause immune-related adverse events(irAEs),which may affect any organs.Early identification and appropriate treatment can improve patient outcome.^(18)F-FDG PET/CT is capable of early detection of irAEs and provides effective clinical guidance.This article reviews the clinical application of^(18)F-FDG PET/CT in detecting irAEs,including typical imaging findings and research progress.

关 键 词：免疫相关不良反应 免疫检查点抑制剂 正电子发射断层显像术 体层摄影术 X线计算机 氟脱氧葡萄糖F18 发展趋势 

分 类 号：R730.44[医药卫生—肿瘤]